FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine

NCT02827201 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

127

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: FOLFIRI.3
DRUG: nab-paclitaxel+ gemcitabine

Sponsor

Federation Francophone de Cancerologie Digestive

Collaborators

[object Object]
[object Object]